Literature DB >> 27392479

Neuroprotective effects of Tongmai Yizhi Decoction () against Alzheimer's disease through attenuating cyclin-dependent kinase-5 expression.

Jing-Han Feng1, Bao-Chang Cai2, Wei-Feng Guo3, Ming-Yan Wang4, Yong Ma1, Qiao-Xi Lu1.   

Abstract

OBJECTIVES: To explore the protective effects of Tongmai Yizhi Decoction (, TYD), a Chinese herb complex prescription against the impairment of cognitive functions and memory loss in amyloid beta 1-40 (Aβ1-40) peptide and ibotenic (IBO)-induced Alzheimer's disease (AD) model rats.
METHODS: The in vivo model was established by injecting Aβ1-40 and IBO into left hippocampal CA1 area of Sprague-Dawley (SD) rat to mimic AD. Totally 32 SD rats were divided into 4 groups, including sham operation group, AD model group, TYD group [AD rats treated with TYD at the dosage of 19.44 g/(kg•d) for 4 weeks] and huperzine A group [AD rats treated with huperzine A at the dosage of 40.5 μg/(kg•d) for 4 weeks]. Spatial learning and memory level was detected by Morris Water Maze test. Histological morphology in the hippocampus was tested by hematoxylin-eosin (HE) staining. Cyclin-dependent kinase-5 (Cdk5) protein and gene expression level were investigated by Western blot analysis and real-time quantitative polymerase chain reaction (RT-qPCR), respectively.
RESULTS: Aβ1-40 and IBO treatment induced longer escape latency of rats, compared with sham operation group from day 25 (P<0.01). However, TYD and huperzine A obviously shortened the escape latency from day 26 (P<0.01). Moreover, the effect of TYD was similar to huperzine A (P>0.05). Furthermore, HE staining also showed that TYD and huperzine A reversed the neuropathological changes in the hippocampus triggered by Aβ1-40 and IBO. TYD and huperzine A effectively reduced the expression levels of Cdk5 protein and gene located in rat hippocampus, compared with the AD model group (P<0.01).
CONCLUSION: TYD could be a promising neuroprotective agent for protecting neuron from AD injury through inhibiting Cdk5 expression.

Entities:  

Keywords:  Alzheimer's disease; Chinese medicine; Tongmai Yizhi Decoction; cyclin-dependent kinase-5

Mesh:

Substances:

Year:  2016        PMID: 27392479     DOI: 10.1007/s11655-016-2507-0

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  9 in total

1.  Cdk5/p25-induced cytosolic PLA2-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration.

Authors:  Jeyapriya R Sundaram; Elizabeth S Chan; Charlene P Poore; Tej K Pareek; Wei Fun Cheong; Guanghou Shui; Ning Tang; Chian-Ming Low; Markus R Wenk; Sashi Kesavapany
Journal:  J Neurosci       Date:  2012-01-18       Impact factor: 6.167

2.  Cdk5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer's disease.

Authors:  Kuei-Hua Chang; Yolanda de Pablo; Hyun-pil Lee; Hyoung-gon Lee; Mark A Smith; Kavita Shah
Journal:  J Neurochem       Date:  2010-03-14       Impact factor: 5.372

Review 3.  Cdk5: a multifaceted kinase in neurodegenerative diseases.

Authors:  Zelda H Cheung; Nancy Y Ip
Journal:  Trends Cell Biol       Date:  2011-12-20       Impact factor: 20.808

Review 4.  Huperzine a as potential treatment of Alzheimer's disease: an assessment on chemistry, pharmacology, and clinical studies.

Authors:  Giang T Ha; Ryan K Wong; Yan Zhang
Journal:  Chem Biodivers       Date:  2011-07       Impact factor: 2.408

Review 5.  Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia.

Authors:  Hai Yan Zhang; Chun Yan Zheng; Han Yan; Zhi Fei Wang; Li Li Tang; Xin Gao; Xi Can Tang
Journal:  Chem Biol Interact       Date:  2008-05-13       Impact factor: 5.192

6.  The anti-inflamm-aging and hepatoprotective effects of huperzine A in D-galactose-treated rats.

Authors:  Qingwei Ruan; Fang Liu; Zhanjuan Gao; Deqiu Kong; Xiaona Hu; Dongmei Shi; Zhijun Bao; Zhuowei Yu
Journal:  Mech Ageing Dev       Date:  2013-01-08       Impact factor: 5.432

7.  Targeting Cdk5 activity in neuronal degeneration and regeneration.

Authors:  Jyotshnabala Kanungo; Ya-li Zheng; Niranjana D Amin; Harish C Pant
Journal:  Cell Mol Neurobiol       Date:  2009-12       Impact factor: 5.046

8.  Nuclear localization of Cdk5 is a key determinant in the postmitotic state of neurons.

Authors:  Jie Zhang; Samantha A Cicero; Li Wang; Rita R Romito-Digiacomo; Yan Yang; Karl Herrup
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-12       Impact factor: 11.205

9.  CDK5 is essential for soluble amyloid β-induced degradation of GKAP and remodeling of the synaptic actin cytoskeleton.

Authors:  Francesco Roselli; Paolo Livrea; Osborne F X Almeida
Journal:  PLoS One       Date:  2011-07-29       Impact factor: 3.240

  9 in total
  4 in total

Review 1.  A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies-Emphasis on Alzheimer's Disease Pathogenesis.

Authors:  Mayuri Shukla; Prapimpun Wongchitrat; Piyarat Govitrapong
Journal:  Neurochem Res       Date:  2022-02-05       Impact factor: 3.996

Review 2.  Selected Natural Products in Neuroprotective Strategies for Alzheimer's Disease-A Non-Systematic Review.

Authors:  Karolina Wojtunik-Kulesza; Tomasz Oniszczuk; Jarosław Mołdoch; Iwona Kowalska; Jarosław Szponar; Anna Oniszczuk
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

Review 3.  Neuroprotective Natural Products for Alzheimer's Disease.

Authors:  Xin Chen; Joshua Drew; Wren Berney; Wei Lei
Journal:  Cells       Date:  2021-05-25       Impact factor: 6.600

Review 4.  Therapeutic Effects of Natural Drugs on Alzheimer's Disease.

Authors:  Yuan Ma; Man-Wen Yang; Xin-Wei Li; Jian-Wei Yue; Jun-Zong Chen; Mei-Wen Yang; Xuan Huang; Lian-Lian Zhu; Fen-Fang Hong; Shu-Long Yang
Journal:  Front Pharmacol       Date:  2019-12-04       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.